Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2024

30-03-2024 | Direct Oral Anticoagulant

Management of direct oral anticoagulant drug interactions in hospitalized patients

Authors: Mohsen H. Al Zaria, Leo F. Buckley, Heather Dell’orfano, Peter Manzo, John Fanikos

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2024

Login to get access

Abstract

Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown. We identified all hospitalized patients at our institution who were admitted with a clinically relevant DOAC DDI from 01/2021 to 06/2021. Clinically relevant DOAC DDIs were defined as those listed in the prescribing information or FDA CYP3A4/Pgp inhibitors clinical indexes. We assessed the prevalence of DOAC DDIs and categorized their management as: drug stopped, drug held, or drug continued. For drugs that were continued we assessed whether the dose of the DOAC or interacting drug was increased, decreased or unchanged during the admission. We ascertained the number of DOAC DDIs that prompted an automated prescribing alert in our electronic health record (EHR). Finally, we conducted a logistic regression model to compare users of DOACs with DDI who had their regimen adjusted versus those without adjustments, focusing on outcomes of rehospitalization and death, adjusting for age and gender. Among 3,725 hospitalizations with a DOAC admission order, 197 (5%) had a clinically relevant DOAC DDI. The DOAC and the interacting drug were continued at discharge for 124 (63%) hospitalizations. The most frequent adjustments were stopping the interacting drug (73%) and stopping the DOAC (15%). Only 7 (4%) of DOAC DDIs prompted an EHR alert. The adjusted odds ratios for rehospitalizations and death, respectively, among patients whose regimens were adjusted compared to those whose were not, were 1.29 (95% CI, 0.67 to 2.48; P = 0.44) and 1.88 (95% CI, 0.91 to 3.89; P = 0.09). Clinically relevant DDIs with DOACs occur infrequently among hospitalized patients and usually are managed without stopping the DOAC. The clinical impact of such DDIs and subsequent adjustments on thrombotic and hemorrhagic outcomes requires further investigation.
Literature
3.
go back to reference Information P (2015) ELIQUIS(R) oral tablets, apixaban oral tablets. Bristol-Myers Squibb Company and Pfizer Inc (per FDA), Princeton, NJ Information P (2015) ELIQUIS(R) oral tablets, apixaban oral tablets. Bristol-Myers Squibb Company and Pfizer Inc (per FDA), Princeton, NJ
4.
go back to reference ‘Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2021 ‘Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2021
5.
go back to reference Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc. (per FDA), Parsippany, NJ, 2015. Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc. (per FDA), Parsippany, NJ, 2015.
6.
go back to reference Information P (2019) XARELTO(R) oral tablets, rivaroxaban oral tablets. NJ, Janssen Pharmaceuticals Inc (per FDA), Titusville Information P (2019) XARELTO(R) oral tablets, rivaroxaban oral tablets. NJ, Janssen Pharmaceuticals Inc (per FDA), Titusville
Metadata
Title
Management of direct oral anticoagulant drug interactions in hospitalized patients
Authors
Mohsen H. Al Zaria
Leo F. Buckley
Heather Dell’orfano
Peter Manzo
John Fanikos
Publication date
30-03-2024
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2024
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-024-02967-2

Other articles of this Issue 4/2024

Journal of Thrombosis and Thrombolysis 4/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.